The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 19, 2016
Filed:
Nov. 12, 2010
Applicants:
Dennis J Thiele, Chapel Hill, NC (US);
Daniel W Neef, Durham, NC (US);
Jose S Mendoza, Chapel Hill, NC (US);
Inventors:
Dennis J Thiele, Chapel Hill, NC (US);
Daniel W Neef, Durham, NC (US);
Jose S Mendoza, Chapel Hill, NC (US);
Assignees:
DUKE UNIVERSITY, Durham, NC (US);
CHAPERONE THERAPEUTICS, INC, Durham, NC (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 231/10 (2006.01); C07D 409/04 (2006.01); C07C 211/01 (2006.01); A61K 31/415 (2006.01); A61K 31/4155 (2006.01); A61K 31/426 (2006.01); A61K 45/06 (2006.01); C07D 231/40 (2006.01); C07D 277/42 (2006.01); C07D 277/60 (2006.01); C07K 14/47 (2006.01); C07D 231/38 (2006.01); C07D 277/38 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01);
U.S. Cl.
CPC ...
C07C 211/01 (2013.01); A61K 31/415 (2013.01); A61K 31/4155 (2013.01); A61K 31/426 (2013.01); A61K 45/06 (2013.01); C07D 231/38 (2013.01); C07D 231/40 (2013.01); C07D 277/38 (2013.01); C07D 277/42 (2013.01); C07D 277/60 (2013.01); C07D 405/14 (2013.01); C07D 409/04 (2013.01); C07D 413/12 (2013.01); C07K 14/47 (2013.01);
Abstract
The present invention relates to substituted pyrazole compounds, methods for their discovery, and their research and therapeutic uses, and pharmaceutical Formulations thereof. In particular, the present invention provides substituted pyrazole compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.